In the absence of red blood cells or any other colloid, human albumin has saved thousands of lives since its first use in 1941. However, for general volume expansion purposes including trauma resuscitation, published evidence suggests that albumin has now been superseded by synthetic colloids, which are more effective volume expanders, have vascular protective effects and are cheaper.
Alexander MR, Ambre JJ, Liskow BI, Trost DC.1979. Therapeutic use of albumin. JAMA241: 2527-2529.
2.
Allison K, Gosling P, Jones S, Pallister I, Porter K.Hydroxyethyl starch reduces capillary leak compared to gelatine solutions during trauma resuscitation. J Trauma1999. 47: 1114-1121.
3.
Boldt J, Heesen M, Welters I, Padberg W, Martin K, Hempelmann G.1995. Does the type of volume therapy influence endothelial-related coagulation in the critically ill?Br J Anaesth75: 740-746.
4.
Boldt J, Heesen M, Muller M, Pabsdorf M, Hempelmann G.1996a. The effects of albumin versus hydroxethyl starch solution on cardiorespiratory and circulatory variables in critically ill patients. Anesth Analg83: 254-261.
5.
Boldt J, Mueller M, Menges T, Papsdorf M, Hempelmann G.1996b. Influence of different volume therapy regimes on regulators of the circulation in the critically ill. Br J Anaesth77: 480-487.
6.
Boldt J, Heesen M, Padberg W, Martin K, Hempelmann G.1996c. The influence of volume therapy and pentoxifylline infusion on circulating adhesion molecules in trauma patients. Anaesthesia51: 529-535.
7.
Bushnell LS. 1975. Respiratory failure and albumin. In: Sgouris JT, Rene eds. Proceedings of the workshop of albumin, Feb. 12-13, 1975, pub. no. 76-925. Bethesda, MD: National Institute of Health, Department of Health and Welfare, 164-164.
8.
Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P.1996. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet348: 1620-1622.
9.
CMS Expert Working Party. 1999. The safety of human albumin, vol. 25. Current problems in pharmacovigilance. London: Medicines Control Agency, 11-11.
10.
Coates JB Jr, McFetridge EM.1964. The bovine and human albumin programs. In: Blood program in World War II, Washington, DC. Washington, DC: Office of the Surgeon General, Department of the Army, 325-357.
11.
Cochrane Injuries Group Albumin Reviewers. 1998. Human albumin administration in critically ill patients: systematic review of randomized controlled trials. BMJ317: 235-240.
12.
Collis RE, Collins PW, Gutteridge CNet al. 1994. The effect of hydroxyethyl starch and other plasma volume substitutes on endothelial cell activation: an in vitro study. Intensive Care Med20: 37-41.
13.
Debrix I, Combeau D, Stephan F, Benomar A, Becker A.1999. Clinical practice guidelines for the use of albumin: results of a drug use evaluation in a Paris hospital: Tenon Hospital, Paris. Pharm World Sci21: 11-16.
14.
Doweiko JP, Nompleggi DJ.1991. Use of albumin as a volume expander. J Parenter Enteral Nutr15: 484-487.
15.
Erstad BL, Gales BJ, Rappaport WD.1991. The use of albumin in clinical practice. Arch Intern Med151: 901-911.
16.
Fleck A, Raines G, Hawker Fet al. 1985. Increased vascular permeability: a major cause of hypoalbuminaemia in disease and injury. Lanceti: 781-784.
17.
Gibbs J, Cull W, Henderson W, Daley J, Hur K, Khuri SF.1999. Preoperative serum albumin as a predictor of operative mortality and morbidity. Arch Surg184: 36-42.
18.
Golub R, Rossento J, Cantu R, Nierman D, Moideen A, Stein H.1994. Efficacy of albumin supplementation in the surgical intensive care unit: a prospective randomized study. Crit Care Med22: 613-619.
19.
Goodwin CW, Direthy L, Lam V, Pruitt BA.1983. Randomized trial of the efficacy of crystalloid and colloid resuscitation on hemodynamic response and lung water following thermal injury. Ann Surg197: 520-531.
20.
Gosling P.1995. Albumin and the critically ill. Care of the Critically Ill11: 57-61.
21.
Greenhalgh DG, Housinger TA, Kagan RJet al. 1995. Maintenance of serum albumin levels in pediatric burn patients: a prospective, randomized trial. J Trauma39: 67-73.
22.
Guthrie RD, Hines CH.1991. Use of intravenous albumin in the critically ill patient. Am J Gastroenterol86: 255-263.
23.
Hallworth MJ, Capps N eds. 1993. Therapeutic drug monitoring and clinical biochemistry. London: ACB Venture, 11-12.
24.
Hofbauer R, Moser D, Hornykewyez S, Frass M, Kapiotis S.1999. Hydroxyethyl starch reduces the chemotaxis of white cells through endothelial cell monolayers. Transfusion39: 289-294.
25.
Jelenko C, Williams JB, Wheeler MLet al. 1979. Studies in shock and resuscitation. I: Use of a hypertonic, albumin-containing, fluid demand regime (HALFD) in resuscitation. Crit Care Med7:157-167.
26.
Kaminski MJ, Williams SD.1990. Review of the rapid normalisation of serum albumin with modified total parenteral nutrition solutions. Crit Care Med18: 327-335.
27.
Klapp D, Harrison W.1979. Evaluation of albumin use by medical audit. Am J Hosp Pharm36: 1205-1209.
28.
Lewis RT.1980. Albumin: role and discriminative use in surgery. Can J Surg23: 322-328.
29.
Lowe RJ, Moss GS, Jilek J, Levine HD.1977. Crystalloid versus colloid in the etiology of pulmonary failure after trauma: a randomized trial in man. Surgery81: 676-683.
30.
Lucas CE, Ledgerwood AM, Higgins RF, Weaver DW.1980. Impaired pulmonary function after albumin resuscitation from shock. J Trauma20: 446-451.
31.
Marik PE, Iglesias J, Maini B.1997. Gastric intramucosal pH changes after volume replacement with hydroxyethyl starch or crystalloid in patients undergoing elective abdominal aortic aneurysm repair. J Crit Care12: 51-55.
32.
Margarson MP, Soni N.1998. Serum albumin: touchstone or totem?Anaesthesia53: 789-803.
33.
Metilda LA, Shackford SR, Virgilio RW, Peters RM.1984. Crystalloid versus colloid in fluid resuscitation of patients with severe pulmonary insufficiency. Surg Gynecol Obstet158: 207-212.
34.
Moss GS, Lowe RJ, Jilek J, Levine HD.1981. Colloid or crystalloid in the resuscitation of hemorrhagic shock: a controlled clinical trial. Surgery89: 434-438.
35.
Offringa M.1998. Excess mortality after human albumin administration in critically ill patients. BMJ317: 223-224.
36.
Oz MC, Fitzpatrick MF, Zikria BA, Pinsky DJ, Duran WN.1995. Attenuation of microvascular permeability dysfunction in post-ischemic striated muscle by hydroxyethyl starch. Microvasc Res50: 71-79.
37.
Parving HH, Gyntelberg F.1973. Transcapillary escape rate of albumin and plasma volume in essential hypertension. Circ Res32: 643-651.
38.
Peters T Jr.1996. All about albumin: biochemistry, genetics and medical applications. San Diego, CA: Academic Press, 3-3, 5-5, 278-278.
39.
Phillips A, Shaper AG, Whincup PH.1989. Association between serum albumin and mortality from cardiovascular disease, cancer and other causes. Lancet335: 1434-1436.
40.
Reinhardt GF, Myscofski JW, Wilkens DBet al. 1980. Incidence and mortality of hypoalbuminaemic patients in hospitalized veterans. J Parenter Enteral Nutr75: 357-359.
41.
Scheirhout G, Roberts I.1998. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomized trials. BMJ316: 961-964.
42.
Schmand JF, Ayala A, Morrison MH, Chaudry IH.1995. Effects of hydroxyethyl starch after trauma-hemorrhagic shock: restoration of macrophage integrity and prevention of increased circulating interleukin-6 levels. Crit Care Med23: 806-814.
43.
Soni N.1995. Wonderful albumin?BMJ310: 887-888.
44.
Thompson WL.1975. Rational use of albumin and plasma substitutes. Johns Hopkins Med J136: 220-225.
45.
Stockwell M, Soni N, Riley B.1992. Colloid solutions in the critically ill. A randomized comparison of albumin and polygeline. 1. Outcome and duration of stay in the intensive care unit. Anaesthesia47: 3-6.
46.
Strubelt O, Younes M, Li Y.1994. Protection by albumin against ischaemia- and hypoxia-induced hepatic injury. Pharmacol Toxicol75: 280-284.
47.
Tullis JT.1977a. Albumin 1: background and use. JAMA237: 355-360.
48.
Tullis JT.1977b. Albumin 2: guidelines for clinical use. JAMA237: 460-463.
49.
Victorian Drug Use Advisory Committee. 1991. Human albumin solutions: an audit of use in three major metropolitan hospitals. Med J Aust154: 657-660.
50.
Vogt N, Bothner U, Brinkmann A, de Petriconi R, Georieff M.1999. Peri-operative tolerance to large-dose HES 2000/0.5 in major urological procedures compared with 5% albumin. Anaesthesia54: 121-127.
51.
Wahba A, Sendtner E, Birnbaum DE. 1987. Fluid resuscitation with Haemacell vs human albumin following coronary artery bypass grafting. Thorac Cardiovasc Surg1996. 44: 178-182.
52.
Whicher J, Spence C.When is albumin worth measuring?Ann Clin Biochem24: 572-580.
53.
Yim JM, Vermeulen LC, Erstad BL, Matuszewski KA, Burnett DA, Vlasses PH.1995. Albumin and nonprotein colloid solutions use in US academic health centers. Arch Intern Med155: 2450-2455.
54.
Younes RN, Yin KC, Amino CJet al. 1998. Use of pentastarch solution in the treatment of patients with hemorrhagic hypovolaemia: randomised phase II study in the emergency room. World J Surg22: 2-5.
